肝星状细胞
纤维化
骨形态发生蛋白
肝纤维化
转化生长因子
SMAD公司
癌症研究
骨形态发生蛋白7
体内
细胞生物学
小RNA
化学
肺纤维化
转化生长因子β
上皮-间质转换
下调和上调
CTGF公司
生物
细胞生长
肌成纤维细胞
内分泌学
内科学
医学
基因
生物化学
生物技术
作者
Feihong Ji,Kuifeng Wang,Yu Zhang,Xin-Li Mao,Qin Huang,Jun Wang,Liping Ye,Youming Li
摘要
Abstract There has been an increasing number of studies about microRNAs as key regulators in the development of hepatic fibrosis. Here, we demonstrate that miR‐542‐3p can promote hepatic fibrosis by downregulating the expression of bone morphogenetic protein 7 (BMP‐7), which is known to antagonize transforming growth factor β1 (TGFβ1)‐mediated fibrogenesis effect. The expression of miR‐542‐3p is increased in activated hepatic stellate cells (HSCs). Downregulation of MiR‐542‐3p by antisense inhibitors can inhibit HSCs activation markers, including α‐smooth muscle actin (α‐SMA) and collagen as well as TGFβ signaling pathways. MiR‐542‐3p was significantly upregulated in carbon tetrachloride (CCl 4 )‐induced hepatic fibrosis in mice, and downregulation of miR‐542‐3p by lentivirus could prevent the development of hepatic fibrosis. In addition, miR‐542‐3p can directly bind to the 3′‐untranslated region of BMP‐7 mRNA, indicating that its profibrotic effect appears to be caused by its inhibition of BMP‐7. Our results suggest that downregulation of miR‐542‐3p prevents liver fibrosis both in vitro and in vivo, highlighting its potential as a novel biomarker or therapeutic target for hepatic fibrosis.
科研通智能强力驱动
Strongly Powered by AbleSci AI